China Biologic Products said its subsidiary, Guizhou Taibang Biological Products, has signed a deal with Xinjiang Deyuan Bioengineering to source 500 tons of raw plasma over the next three years, the company said in a news release.
China's decades-long quest to have its sciences recognized as coming of age by international bodies got a huge boost with the awarding this week of the Nobel Prize in physiology or medicine to Chinese researcher Tu Youyou for developing an antimalarial medicine derived from an ancient remedy. But problems remain for China's scientists and researchers caught in a quality-versus-quantity trap.
China oncology biotech BeiGene has snapped up Changzhen Wu to head a manufacturing operation that is in the process of outfitting a major facility in Suzhou, building on another key hire snatched from WuXi AppTec to build out a formidable team.
Bristol-Myers Squibb is the latest Big Pharma to pay up for bribery in China. The U.S.-based drugmaker agreed to a $14.7 million settlement with the Securities and Exchange Commission, to wrap up charges that its Chinese joint venture shelled out cash and other incentives to boost scripts for its drugs.
Venture-backed Ark Biosciences has successfully completed a Phase I clinical trial of work on anti-respiratory syncytial virus (RSV) candidate AK0529, hitting a key milestone for the respiratory viral infection and viral hepatitis focused company.
Expectations that the U.S. FDA is ready to take a harder look at products from China, mirroring efforts seen in India in the past few years, has brought the shortage of inspection manpower for drug manufacturing in China into sharper focus.
U.S. biotech DelMar Pharmaceuticals will present an update on pediatric brain tumor indication oncology candidate VAL-083 as it works to expand potential for a drug now approved in China for CML and lung cancer. The candidate has received orphan drug designation in Europe and the U.S. for the treatment of gliomas.
China's commerce ministry has lightly slapped a unit of Shanghai Fosun Pharmaceutical Group with a fine for acquiring a stake in a Suzhou-based company without government approval.
Genovate Biotechnology of Taiwan has begun the first phase of the construction of a $55 million insulin-manufacturing facility in China. The company says it will eventually lead to a $1 billion investment that will help it win government contracts in the country.
China Daily posted an interview with Bill Gates, co-founder of Microsoft and co-chair of the Bill & Melinda Gates Foundation, who lauded the country's efforts to build on reforms that have transformed access to healthcare services in the world's most populous country.